Sign in
CompletedPhase 1/2

Safety and Immunogenicity of GPO Seasonal Tetravalent Inactivated Split Virion Influenza Vaccine in Healthy Thais

Key facts

Who runs it
Mahidol University
Where
Thailand1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 1/2
People taking part
250 people enrolled
Started
4 Nov 2023
Ended
28 Jan 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • TetraFluvac TF vaccine
  • Vaxigrip vaccine
Record updated
8 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part
Show the full registry criteria (20)Hide the full registry criteria

Who can take part

  • Aged 18 years and above
  • Having Thai ID card or equivalent
  • Able to read and provide written informed consent prior to performance of any study-specific procedure
  • Healthy as defined by no clinically significant acute medical condition, and no chronic medical condition that has not been controlled within 90 days of randomization, as determined by medical history, physical examination, screening laboratory test results, and clinical assessment of the investigator
  • All hematology, biochemistry and urine analysis are within normal range or of no clinical significance (not higher than 1.5 time of normal value without any clinical finding from history and physical examination)

Who cannot take part

  • History of immunosuppression < 6 months prior to immunization
  • The participants who have been taking immunoglobulin products or have had a blood transfusion during past 3 months before the beginning of the experiment
  • Current alcohol abuse or drug addiction that might interfere with the ability to comply with trial procedures
  • Known history of egg allergy
  • Having had recently influenza infection confirmed as H1N1, H3N2, or Flu B within 3 months preceding enrollment to the trial
  • History of bronchial asthma, chronic lung diseases, chronic rhinitis
  • History of immunodeficiency state
  • History of anaphylactic or other allergic reactions to influenza vaccine or any vaccine component or excipient (e.g. gentamicin or thimerosal)
  • Acute infectious with fever > 38 degree Celsius and noninfectious diseases (within 72 hours) preceding enrollment in the trial
  • Any condition that in the opinion of the investigator would pose a health risk to the subject if enrolled, or could interfere with the evaluation of the vaccine
  • Any test for HIV, HBsAg, Hep C antibody shows positive results with clinically significance
  • Vaccination against influenza in the past 6 months preceding enrollment to the trial
  • Participation in other research study
  • Pregnancy or plan to become pregnant for 60 days after enrollment or breast feeding
  • Employee of any person employed by the Sponsor, the contract research organization (CRO), the PI, study site personnel, or site

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The study is aim to evaluate the safety and immunogenicity of one dose TetraFluvac TF vaccine (15 μg HA per strain per dose) of the GPO seasonal quadrivalent inactivated split virion influenza vaccine in healthy adults aged 18 years and above over 90 days post-injection.

The 2 groups in the trial

  • TetraFluvac TF vaccineTreatment being tested

    20 participants in phase I study and 200 participants in phase II study will receive a prefilled single dose of 0.5 ml of TetraFluvac TF vaccine will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.

  • Vaxigrip vaccineExisting treatment, for comparison

    20 participants in phase I study and 50 participants in phase II study will receive a prefilled single dose of 0.5 ml Vaxigrip vaccine (Commercially available seasonal quadrivalent split, manufactured by Sanofi Pasteur, Ltd. France) will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase I/II Randomized Double Blind Controlled Study to Evaluate the Safety and Immunogenicity of GPO Seasonal Tetravalent Inactivated Split Virion Influenza Vaccine in Healthy Thais
Record updated
8 October 2026